NEW FRONTIERS IN HEMATOLOGIC RESEARCH: QUALITY OF LIFE AND ARTIFICIAL INTELLIGENCE GIMEMA INTERNATIONAL MEETING

• MASSIMO BRECCIA· DIRIGENTE MEDICO/RESPONSABILE UOS
• FABIO EFFICACE· DIRETTORE DI RICERCA

• GREGORY ABEL· RELATORE
• MASSIMO BRECCIA· RELATORE
• GIOVANNI CAOCCI· MODERATORE
• MARTA CIPRIANI· RELATORE
• GARY COLLINS· RELATORE
• MATTEO GIOVANNI DELLA PORTA· RELATORE
• FABIO EFFICACE· RELATORE
• CARMELO GURNARI· RELATORE
• CLAIRE HARRISON· RELATORE
• MARIO LUPPI· MODERATORE
• FABRIZIO PANE· MODERATORE
• JOHN DEVIN PEIPERT· RELATORE
• ALFONSO PICIOCCHI· MODERATORE
• LEONARDO POTENZA· RELATORE
• GIUSEPPE TORO· RELATORE
• LONNEKE VAN DE POLL· RELATORE
• ALESSANDRO MARIA VANNUCCHI· MODERATORE
• ADRIANO VENDITTI· MODERATORE
• MARCO VIGNETTI· RELATORE
• MARIA TERESA VOSO· MODERATORE
• AMER ZEIDAN· RELATORE
• PIER LUIGI ZINZANI· RELATORE

Ragione sociale

STUDIO E.R. CONGRESSI S.R.L.

Stato accreditamento

STANDARD - 1° rinnovo

Di sistema

Notable treatment advances have been made in the last decade for patients with hematologic malignancies and several new drugs are under development. Within this rapidly evolving landscape in hematology, the inclusion of quality of life (qol) and other patient-reported outcomes (pros) is critical to inform benefit/risk assessment of new therapies, or to assess whether patients live longer and better. Another key aspect in the current hematology arena, is the use of artificial intelligence (ai) and this meeting will also address some of the most relevant opportunities and challenges in this novel area. The underlying theme of the meeting is the central role of patients in hematology practice and research and the value of patient-centricity in drug development process, hence the value of patient-associations will also be discussed during the meeting

#2Linee guida - protocolli - procedure

Area: Obiettivi formativi tecnico-professionali

Partecipanti max

150

Verifica presenza

Firma Di Presenza

Verifica apprendimento

Questionario A Risposta Multipla Online